BioNTech and Bristol Myers Squibb sign monster deal
BioNTech and Bristol Myers Squibb have signed a global partnership to jointly develop and commercialize BioNTech's promising bispecific antibody BNT327. The agreement is worth up to USD 11,1 billion and...